The US Patent and Trademark Office (USPTO) has granted a new patent No. 8262611 to Advanced Catheter Therapies' Occlusion Perfusion Catheter (OPC).
The new patent, which is similar to the company’s patent No. 8088103 received in early 2012, covers the delivery of pharmaceuticals, live cells and biologics to treat a variety of disease states and place the agent circumferentially into the vasculature of the treatment chamber.
The company said by temporarily occluding a specific region from blood flow, the multilumen balloon OPC catheter can deliver therapeutic agents to the peripheral and eventually the coronary vasculature.
Advanced Catheter Therapies CEO Paul Fitzpatrick said with the issuance of new patent, the company is pleased to further strengthen its intellectual property platform.
"We continue to move the OPC closer to commercialization while exploring new tools to help support physicians in their work," Fitzpatrick added.